Psychedelics ETF to Launch After Sector Attracts Thiel’s Money
Bloomberg 1/26/2021 Michael Bellusci
(Bloomberg) The world’s first exchange-traded fund for psychedelic-drug companies will debut this week in Toronto, as the investment industry tries to capitalize on rising interest in prospective mental health treatments using the drugs.
The Horizons Psychedelic Stock Index ETF, listed as PSYK, is expected to start trading Wednesday on the NEO Exchange, its operator said. The fund will track the North American Psychedelics Index.
Companies that work with drugs containing compounds such as psilocybin, the substance in magic mushrooms that produces psychedelic effects, are multiplying. Some early-stage investors are betting the drugs could disrupt the $70 billion market for mental health treatment. The wave of enthusiasm over cannabis shares in recent years has, in some ways, spread to these drugs that were long associated with all-night rave parties.
Psychedelics ETF to launch after sector attracts Thiel s money
Michael Bellusci, Bloomberg News Peter Thiel , Bloomberg
The worldâs first exchange-traded fund for psychedelic-drug companies will debut this week in Toronto, as the investment industry tries to capitalize on rising interest in prospective mental health treatments using the drugs.
The Horizons Psychedelic Stock Index ETF, listed as PSYK, is expected to start trading Wednesday on the NEO Exchange, its operator said. The fund will track the North American Psychedelics Index.
Companies that work with drugs containing compounds such as psilocybin, the substance in magic mushrooms that produces psychedelic effects, are multiplying. Some early-stage investors are betting the drugs could disrupt the US$70 billion market for mental health treatment. The wave of enthusiasm over cannabis shares in recent years has, in some ways, spread to these drugs that were long a
Article content
The world’s first exchange-traded fund for psychedelic-drug companies will debut this week in Toronto, as the investment industry tries to capitalize on rising interest in prospective mental health treatments using the drugs.
The Horizons Psychedelic Stock Index ETF, listed as PSYK, is expected to start trading Wednesday on the NEO Exchange, its operator said. The fund will track the North American Psychedelics Index.
We apologize, but this video has failed to load.
Try refreshing your browser, or Psychedelics ETF to launch in Toronto after sector attracts Peter Thiel s money Back to video
Companies that work with drugs containing compounds such as psilocybin, the substance in magic mushrooms that produces psychedelic effects, are multiplying. Some early-stage investors are betting the drugs could disrupt the US$70 billion market for mental health treatment. The wave of enthusiasm over cannabis shares in recent years has, in some ways, spread to these drugs
MINDCURE Included in First Psychedelic ETF & North American Psychedelics Index
News provided by
Share this article
Share this article
Mind Cure among respected life science and therapeutic technology peers in first ever Psychedelic ETF & North American Psychedelic Index
VANCOUVER, BC, Jan. 21, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Company ) is pleased to announce its inclusion among 17 psychedelic companies in the first ever Psychedelic ETF. Horizon s Psychedelic ETF, is expected to commence trading Jan. 26, 2021 under ticker PSYK on the NEO exchange.
The ETF includes companies in the Canadian legal psychedelics industry, as well as U.S. companies engaged in legal activities involving psychedelic drugs and substances. The purpose of the ETF is to invest in, and indirectly derive revenues from, companies in the psychedelics industry engaged in legal activities involving psychedelic drugs and substances.
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
News provided by
Share this article
Share this article
The strategic partnership between Mind Cure and ATMA will bridge access to research locations for psychedelic drug research while providing patient data for iSTRYM
, Mind Cure s digital therapeutics platform.
VANCOUVER, BC, Jan. 12, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( Mind Cure or the
LOI ) for strategic investment and commercial cooperation with
ATMA Journey Centers Inc. (
ATMA ), a Calgary-based organization. ATMA is the first commercial treatment center in Canada to announce providing psychedelic-assisted therapy for a section 56 exempt patient. The LOI is intended to help Mind Cure secure an equity position within ATMA, empowering the Company with access to a global release strategy for